NOVATO, Calif., Oct. 07, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RARE), a biopharmaceutical company focused on the development of ...

Sharekhan is bullish on Zydus Lifesciences has recommended buy rating on the stock with a target price of Rs 1268 in its ...

Ahmedabad: Zydus Lifesciences Ltd, Ahmedabad has signed a collaborative research agreement with Central Drug Research ...

The UT administration's Drugs Control Wing conducted extensive raids on chemist shops in Manimajra, uncovering violations including unlicensed drug sales and absence of qualified pharmacists.

After five years of research, CDRI discovers a promising protein-drug combo targeting osteoporosis induced by chronic kidney ...

A collaborative research agreement was inked between the parties to develop oral medication through the discovery of small ...

NOVATO, Calif., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that it will present seven abstracts related to its ongoing late-stage program ...

As a result, a large unmet medical need remains for the development of new osteoporosis therapies. AGA2118 is a Sclerostin x DKK1 bispecific antibody in clinical development for the treatment of ...

Moreover, a neutralizing antibody blocking the Wnt signaling inhibitor sclerostin has recently been established as a novel osteoanabolic treatment option for osteoporotic patients. Importantly, ...

Romosozumab attaches itself to a natural substance in the body called sclerostin, which regulates the formation and breakdown of bone. It is the first new osteoporosis treatment in a decade.